Randomized trial shows hemodynamic benefits of 3-hydroxybutyrate in chronic heart failure patients, suggesting a new treatment option.
3-OHB has beneficial hemodynamic effects in HFrEF patients without impairing MEE. These beneficial effects are detectable in the physiological concentration range of circulating 3-OHB levels. The hemodynamic effects of 3-OHB were observed in both HFrEF patients and age-matched volunteers. 3-OHB may potentially constitute a novel treatment principle in HFrEF patients.
No takes yet. Share an insight, caveat, or question.
Nielsen et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: